Polyrizon Ltd. (PLRZ), a development-stage biotech company, Friday announced that it has signed a non-binding Letter of Intent Or LOI with a biotech company focused on psychedelic-derived therapeutics to develop a novel intranasal formulation for psychedelic-based treatments.
This collaboration aims to leverage Polyrizon's proprietary intranasal platform to enhance the delivery of psychedelic treatments, improving bioavailability, efficacy, and patient accessibility.
Polyrizon will lead the formulation's development, utilizing its mucoadhesive drug delivery technology, while the psychedelic company will fund the research and development process, including feasibility studies.
The two companies intend to negotiate a definitive agreement following proof of concept, which will outline intellectual property ownership, commercialization rights, and financial terms.
If successful, this collaboration has the potential to significantly advance clinical development in the psychedelic medicine space, with Polyrizon receiving royalty payments for any future commercialization.
This milestone represents a key step for Polyrizon as it explores new applications for its intranasal platform in the growing field of psychedelic therapeutics.
Currently, PLRZ is trading at $0.54, down by 22.57 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.